Compare Innovative Industrial Properties Inc (IIPR) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innovative Industrial Properties Inc vs Novo Nordisk A/S — how do they compare? Innovative Industrial Properties Inc trades at $63.1 (market cap $1.87B), while Novo Nordisk A/S trades at $49.54 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 117.9× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays the higher dividend (11.81%). Which is the better fit depends on your goals.
| IIPR | NVO | |
|---|---|---|
Market Cap | $1.87B | $220.53B |
Sector | Real Estate | Health |
52-Week High | $64.67 | $71.70 |
52-Week Low | $44.58 | $35.29 |
Enterprise Value | $2.25B | $239.49B |
Dividend Yield | 11.81% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IIPR trades at $64.35, down slightly today, amid a bullish technical trend with strong moving average support. The REIT reported mixed quarterly earnings, with a significant beat in Q4 2025 but a miss in Q1 2026, while maintaining a high dividend yield. Recent news highlights successful debt management and cannabis rescheduling progress as positive catalysts.
Outlook is cautiously optimistic given the strong balance sheet and regulatory tailwinds, but risks include revenue volatility and high dividend payout. Analyst sentiment is mixed with a slight Hold bias, reflecting concerns over near-term earnings consistency versus long-term growth potential in the cannabis real estate sector.
Novo Nordisk (NVO) trades at $49.68, down 1.27% on the day, amid a bullish technical signal from moving averages. The company demonstrates robust fundamentals with a trailing P/E of 12.08 and a net income margin of 37.2%, supported by three consecutive quarterly earnings beats. Recent positive catalysts include EU and Indian regulatory approvals for its oral Wegovy weight-loss pill, expanding its GLP-1 franchise.
The outlook remains positive given strong analyst consensus (57.9% Buy ratings) and projected earnings growth, though risks include intensifying competition in the weight-loss drug market and potential margin pressure. The stock presents a compelling opportunity for investors seeking exposure to a profitable leader in metabolic diseases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
